Smoking increases risk of second primary lung cancer (SPLC)
the ONA take:
According to a new study published in the journal Cancer, researchers have found that increased tobacco exposure is linked with a higher risk of developing second primary lung cancers (SPLCs) and current smokers have an elevated risk of mortality compared with former and never-smokers.
For the study, researchers identified 1,484 patients who underwent surgery for non-small cell lung cancer (NSCLC) bettween 1995 and 2008. The researchers then analyzed the rates of SPLC based on smoking status and history and examined overall survival, local control, distant metastases, and postoperative mortality.
Of the 1,484 patients identified, 98 were never-smokers. The researchers found that the incidence of SPLC at 3, 5, and 8 years was 5%, 8%, and 16%, respectively. Of the never-smokers, only 1 developed an SPLC. Analyses showed that smoking history was the only independent risk factor for developing SPLC (HR, 1.08; 95% CI: 1.02-1.16, P = 0.031), which results in an 8% increased risk for developing the disease per 10 pack-year history.
Researchers found similar rates of local control and distant metastases among all smoking smoking statuses. Never-smokers had a decreased postoperative mortality compared with ever-smokers.
Increased tobacco exposure is linked with a higher risk of developing second primary lung cancers.
The objective of the current study was to determine the effect of smoking on the development of second primary lung cancers (SPLCs) and other clinical outcomes after surgery for non–small cell lung cancer (NSCLC). SPLCs are rare in never–smokers.
Increasing tobacco exposure is associated with a higher risk of SPLC in patients with a history of smoking. Current smokers have an increased risk of mortality whereas former and never–smokers have comparable survival.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|